We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality.
A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside preclinical development activities and fundraising efforts.
The evolution from imitation to innovation has created an ecosystem designed to reward novel science and transformative treatment approaches — and Swiss companies are now claiming their stake.
Tuesday, February 24, 2026
Rare and ultra-rare disease patients have long been forced to struggle upstream.
Wednesday, February 18, 2026
As advanced therapies transition from promising science to industrial maturity, investors will increasingly favor late-stage programs with strong data, proven scalability and credible paths to adoption.
Monday, February 09, 2026
A decentralized model for cell-based products offers various benefits including fresh tissues and drug products, reduced costs, and shorter treatment times.
Wednesday, February 04, 2026
There is significant opportunity to expand the applications of cell therapy further into rare diseases as well as to tackle widespread conditions.
Tuesday, January 27, 2026
Sponsors with a licensed gene therapy can use the same vector platform to reference manufacturing, analytical and safety data for other candidates.
Tuesday, January 20, 2026
A powerful shift is underway within the rare disease space. It started as a handful of inspiring stories of parents stopping at nothing to save the lives of their children. But while this patient advocacy-driven movement is compelling — it shouldn’t have to exist.
Tuesday, January 13, 2026
Characterizing 2025 from a regulatory perspective is uniquely challenging. Perhaps David Bowie said it best when he said, “I don’t know where I’m going from here, but I promise it won’t be boring.”